Anaptysbio, Inc
ANAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001370053
No open-market purchases or sales by Anaptysbio, Inc insiders were filed in the last 90 days; 213 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Anaptysbio, Inc as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- +3 vs. Q1 2023
- Shares held
- 30.2M
- −807.6K (−2.6%) vs. Q1 2023
- Total value
- $614.9M
- −$60.4M (−8.9%) vs. Q1 2023
- New holders
- 14
- 38 more added
- Sold out
- 11
- 35 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 213 | $2.03B |
| Q1 2026 | 208 | $1.55B |
| Q4 2025 | 179 | $1.42B |
| Q3 2025 | 166 | $980.2M |
| Q2 2025 | 148 | $816.2M |
| Q1 2025 | 153 | $742.8M |
| Q4 2024 | 136 | $468.9M |
| Q3 2024 | 160 | $1.13B |
| Q2 2024 | 135 | $746.6M |
| Q1 2024 | 133 | $658.1M |
| Q4 2023 | 119 | $646.4M |
| Q3 2023 | 116 | $544.5M |
| Q2 2023 | 116 | $614.9M |
| Q1 2023 | 113 | $675.4M |
| Q4 2022 | 118 | $1.02B |
| Q3 2022 | 114 | $830.6M |
| Q2 2022 | 124 | $632.6M |
| Q1 2022 | 131 | $735.4M |
| Q4 2021 | 136 | $964.4M |
| Q3 2021 | 127 | $748.8M |
| Q2 2021 | 122 | $720.6M |
| Q1 2021 | 122 | $628.6M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Anaptysbio, Inc; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | 495,054 | $10.1M | 0.04% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 613,000 | $12.5M | 0.27% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 775,924 | $15.8M | 0.09% | 00.0% | Unchanged |
| Great Point Partners LLC | 894,333 | $18.2M | 3.64% | +90,000+11.2% | Added |
| Frazier Life Sciences Management, L.P. | 899,700 | $18.3M | 1.09% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 904,912 | $18.4M | 0.01% | −53,748−5.6% | Reduced |
| Woodline Partners LP | 1,034,549 | $21.0M | 0.25% | +574,987+125.1% | Added |
| Braidwell LP | 1,154,423 | $23.5M | 0.77% | +181,350+18.6% | Added |
| State Street Corp | 1,212,814 | $24.7M | 0.00% | +62,867+5.5% | Added |
| Boxer Capital, LLC | 1,300,000 | $26.4M | 1.23% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 1,459,909 | $29.7M | 0.10% | −221,238−13.2% | Reduced |
| Vanguard Group Inc | 1,775,697 | $36.1M | 0.00% | −43,429−2.4% | Reduced |
| BlackRock Inc. | 1,824,705 | $37.1M | 0.00% | −70,789−3.7% | Reduced |
| Tang Capital Management LLC | 1,950,609 | $39.7M | 5.84% | −81,952−4.0% | Reduced |
| EcoR1 Capital, LLC | 7,521,024 | $153.0M | 4.03% | 00.0% | Unchanged |
| IFP Advisors, Inc | 18 | – | – | 00.0% | Unchanged |
| Jupiter Asset Management Ltd | 0 | $0 | 0.00% | −27,991−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −23,603−100.0% | Sold out |
| Candriam Luxembourg S.C.A. | 0 | $0 | 0.00% | −20,205−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −12,820−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −11,957−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −10,663−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −10,235−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −230−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −164−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |